Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

NCT02349503 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Congenital Adrenal Hyperplasia

Interventions

DRUG: NBI-77860
DRUG: NBI-77860
DRUG: NBI-77860

Sponsor

Neurocrine Biosciences